Pushing the Envelope on the Indications and Doses of Pulmonary Arterial Hypertension Medications

Fares, Wassim H.

doi:10.1097/fjc.0000000000000375

Cited by 1 publication

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These drugs target three main pathways: the nitric oxide, endothelin-1, and prostacyclin pathways; and they currently include five families of drugs: phosphodiesterase type-5 inhibitors (PDE5-I), guanylate cyclase stimulator, endothelin receptor antagonists (ERA), prostacyclin analogues, and selective prostacyclin receptor agonists. [5][6][7] The availability of different classes of medications, different routes, and total number of available PAH-specific medications makes the number of potential transitions within the same class or between classes relatively large. These transitions are already occurring not uncommonly in clinical practice, and there may be pressure by external forces (i.e.…”

Section: Introductionmentioning

confidence: 99%

A systematic review of transition studies of pulmonary arterial hypertension specific medications

Sofer

Ryan²,

Tedford

et al. 2017

Pulm. circ.

Self Cite

View full text Add to dashboard Cite

Pulmonary arterial hypertension (PAH) is a progressive potentially fatal disease. Multiple pharmacologic options are now available, which facilitated transitions between different therapeutic options, although the evidence for such transitions has not been well described. We sought to review the evidence supporting the safety and/or efficacy of transitioning between PAH-specific medications. We performed a systematic review of all published studies in the Medline database between 1 January 2000 and 30 June 2016 reporting on any transition between the currently Food and Drug Administration (FDA)-approved PAH-specific medications. Studies reporting on three or more adult patients published in the English language reporting on transitions between FDA-approved PAH medications were extracted and tabulated. Forty-one studies met the selection criteria, nine of which included less than eight patients (and thus were reported separately in the supplement), for a total of 32 studies. Transitioning from parenteral epoprostenol to parenteral treprostinil appears to be safe and efficacious in patients who have less severe disease and more favorable hemodynamics. Transitioning from a prostacyclin analogue to an oral medication may be successful in patients who have favorable hemodynamics and stable disease. There is conflicting evidence supporting the transition from a parenteral to an inhaled prostacyclin analogue, even in patients who are on background oral therapy. Currently, the only evidence in support of transitioning between oral PDE5 inhibitors is from sildenafil to tadalafil. Patients on higher doses of sildenafil are more likely to fail. In patients with liver abnormalities due to bosentan or sitaxentan, the transition to ambrisentan appears to be safe and can result in clinical improvement. Studies regarding PAH medication transitions are limited. Patients who have less severe disease, better functional status, and are on lower medications doses may be more successful at transitioning.

show abstract

Section: Introductionmentioning

confidence: 99%